APO Research

APO RESEARCH · REPORT

Pneumococcal 13-valent Conjugate Vaccine

Selected research

Industry Growth & Trends

Global Pneumococcal 13-valent Conjugate Vaccine Industry Growth and Trends Forecast to 2032

Market perspective

The global Pneumococcal 13-valent Conjugate Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumococcal 13-valent Conjugate Vaccine include Pfizer, BIOKANGTAI and Walvax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pneumococcal 13-valent Conjugate Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pneumococcal 13-valent Conjugate Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pneumococcal 13-valent Conjugate Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pneumococcal 13-valent Conjugate Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pneumococcal 13-valent Conjugate Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pneumococcal 13-valent Conjugate Vaccine Market by Company

Pfizer

BIOKANGTAI

Walvax

Pneumococcal 13-valent Conjugate Vaccine Segment by Type

0.5ml

Other

Pneumococcal 13-valent Conjugate Vaccine Segment by Application

Hospital

Clinic

Pneumococcal 13-valent Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal 13-valent Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal 13-valent Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal 13-valent Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumococcal 13-valent Conjugate Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pneumococcal 13-valent Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 0.5ml Table 2. Major Company of Other Table 3. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 5. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 10. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 15. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 17. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Pneumococcal 13-valent Conjugate Vaccine Industry Trends Table 25. Pneumococcal 13-valent Conjugate Vaccine Industry Drivers Table 26. Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges Table 27. Pneumococcal 13-valent Conjugate Vaccine Industry Restraints Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Company (2021-2026) & (K Units) Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Sales Share by Company (2021-2026) Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Pneumococcal 13-valent Conjugate Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Pneumococcal 13-valent Conjugate Vaccine Major Company Production Sites and Headquarters Table 35. Global Pneumococcal 13-valent Conjugate Vaccine Company, Product Type & Application Table 36. Global Pneumococcal 13-valent Conjugate Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Pneumococcal 13-valent Conjugate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 41. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 57. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Pneumococcal 13-valent Conjugate Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 62. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 64. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 68. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 75. Pfizer Recent Development Table 76. BIOKANGTAI Company Information Table 77. BIOKANGTAI Business Overview Table 78. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 80. BIOKANGTAI Recent Development Table 81. Walvax Company Information Table 82. Walvax Business Overview Table 83. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 85. Walvax Recent Development Table 86. North America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 87. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 88. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 89. North America Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 90. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Country (2027-2032) Table 91. North America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 92. North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 93. North America Pneumococcal 13-valent Conjugate Vaccine Market Share by Country (2021-2026) Table 94. North America Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 95. North America Pneumococcal 13-valent Conjugate Vaccine Market Share Forecast by Country (2027-2032) Table 96. Europe Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 97. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 98. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 99. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 100. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Country (2027-2032) Table 101. Europe Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 103. Europe Pneumococcal 13-valent Conjugate Vaccine Market Share by Country (2021-2026) Table 104. Europe Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. Europe Pneumococcal 13-valent Conjugate Vaccine Market Share Forecast by Country (2027-2032) Table 106. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 108. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 109. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 110. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Country (2027-2032) Table 111. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 113. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Share by Country (2021-2026) Table 114. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Share Forecast by Country (2027-2032) Table 116. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 118. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 119. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 120. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Country (2027-2032) Table 121. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 123. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Share by Country (2021-2026) Table 124. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Share Forecast by Country (2027-2032) Table 126. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 128. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 129. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Country (2027-2032) Table 131. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 133. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Share by Country (2021-2026) Table 134. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Share Forecast by Country (2027-2032) Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Pneumococcal 13-valent Conjugate Vaccine Distributors List Table 139. Pneumococcal 13-valent Conjugate Vaccine Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Pneumococcal 13-valent Conjugate Vaccine Image Figure 2. Global Pneumococcal 13-valent Conjugate Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal 13-valent Conjugate Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 5. 0.5ml Image Figure 6. Global 0.5ml Sales YoY Growth (2021-2032) & (K Units) Figure 7. Other Image Figure 8. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Pneumococcal 13-valent Conjugate Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Pneumococcal 13-valent Conjugate Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Pneumococcal 13-valent Conjugate Vaccine Market Share by Application 2025 VS 2032 Figure 29. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application in 2025 Figure 30. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application in 2025 Figure 31. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share in Value by Application in 2025 Figure 39. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Pneumococcal 13-valent Conjugate Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Pneumococcal 13-valent Conjugate Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Pneumococcal 13-valent Conjugate Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Pneumococcal 13-valent Conjugate Vaccine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • 0.5ml
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Pfizer
  • BIOKANGTAI
  • Walvax

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pneumococcal 13-valent Conjugate Vaccine Market by Type
  6. 1.3.1 0.5ml
  7. 1.3.2 Other
  8. 1.4 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  9. 1.4.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Pneumococcal 13-valent Conjugate Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Pneumococcal 13-valent Conjugate Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pneumococcal 13-valent Conjugate Vaccine Industry Trends
  2. 2.2 Pneumococcal 13-valent Conjugate Vaccine Industry Drivers
  3. 2.3 Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal 13-valent Conjugate Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Pneumococcal 13-valent Conjugate Vaccine Price (2021-2026)
  4. 3.4 Global Pneumococcal 13-valent Conjugate Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumococcal 13-valent Conjugate Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Pneumococcal 13-valent Conjugate Vaccine Company, Product Type & Application
  7. 3.7 Global Pneumococcal 13-valent Conjugate Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumococcal 13-valent Conjugate Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumococcal 13-valent Conjugate Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumococcal 13-valent Conjugate Vaccine Tier 1, Tier 2, and Tier 3
4 Pneumococcal 13-valent Conjugate Vaccine Regional Status and Outlook
  1. 4.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pneumococcal 13-valent Conjugate Vaccine Historic Market Size by Region
  3. 4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pneumococcal 13-valent Conjugate Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pneumococcal 13-valent Conjugate Vaccine by Application
  1. 5.1 Pneumococcal 13-valent Conjugate Vaccine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  5. 5.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 BIOKANGTAI
  8. 6.2.1 BIOKANGTAI Company Information
  9. 6.2.2 BIOKANGTAI Business Overview
  10. 6.2.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  12. 6.2.5 BIOKANGTAI Recent Developments
  13. 6.3 Walvax
  14. 6.3.1 Walvax Company Information
  15. 6.3.2 Walvax Business Overview
  16. 6.3.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  18. 6.3.5 Walvax Recent Developments
7 North America by Country
  1. 7.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country
  2. 7.1.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  6. 7.2.1 North America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country
  2. 8.1.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  6. 8.2.1 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pneumococcal 13-valent Conjugate Vaccine Sales by Country
  2. 10.1.1 South America Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  6. 10.2.1 South America Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pneumococcal 13-valent Conjugate Vaccine Value Chain Analysis
  2. 12.1.1 Pneumococcal 13-valent Conjugate Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process
  7. 12.2 Pneumococcal 13-valent Conjugate Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
  10. 12.2.3 Pneumococcal 13-valent Conjugate Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research